"Patients who improved were those who started with low CCR5 on their T cells, suggesting their immune system was less active than normal, and levels of CCR5 actually increased in people who improved. This leads to the new hypothesis that long COVID in some persons is related to the immune system being suppressed and not hyperactive."

Caught my eye as well. This may explain our delay in staging a ph2 LH trial. Combined with financial constrictions, and mistakes/failures in previous Covid trials, the added complexity is without our reach to resolve. Even though we have a molecule that will prove to be part of the solution.

IMO,
chazzle